Chondroitin Sulphate for Dogs: Joint Mobility, Inflammation & Whole-Body Support

Chondroitin – More Than Just Joint Support for Dogs

Summary

If your dog is slowing down on walks, struggling to rise after rest, or showing stiffness that wasn’t there a year ago, there’s a good chance their joint cartilage is losing one of its most important structural molecules: chondroitin sulphate.

Chondroitin sulphate is the compound that gives cartilage its cushioning ability — it attracts and holds water, creating the resilient, shock-absorbing gel that protects your dog’s joints every time they move. When chondroitin levels decline — through age, wear, or the inflammatory cycle of osteoarthritis — cartilage loses its ability to bounce back, and the pain, stiffness and reduced mobility that follow are often the first signs owners notice.

But here’s what many dog owners don’t realise: chondroitin sulphate isn’t only a joint molecule. It’s found throughout your dog’s body — in the protective lining of the bladder, the structure of the cornea, the resilience of the skin, and even the mucous membranes of the gut. Supplementing with chondroitin doesn’t just support joints; it contributes to a network of tissues that all rely on the same foundational building blocks.

Perhaps most surprisingly, recent research shows that chondroitin also acts as a prebiotic-like substrate in the gut, feeding beneficial bacteria and increasing production of butyrate — a potent anti-inflammatory compound. This means chondroitin supplementation connects directly to the gut–joint axis: the emerging science showing that gut health and joint health are far more intertwined than previously understood.

In this guide, we examine the evidence behind chondroitin sulphate for dogs — from landmark canine clinical trials to its multi-system benefits, its role in the gut microbiome, and why Bonza chose GreenDroitin®, a plant-derived chondroitin from Tremella fuciformis fungus that achieves superior intestinal absorption at a fraction of the dose of conventional animal-sourced alternatives.

---

Key Takeaways

• Chondroitin sulphate is a naturally occurring glycosaminoglycan (GAG) that gives cartilage its elasticity, water-retention capacity and resistance to compression — making it a foundational structural molecule for healthy joints.
• In canine osteoarthritis studies, glucosamine–chondroitin supplementation has demonstrated statistically significant improvements in pain scores, weight-bearing and overall condition severity, with effects typically emerging after 6–10 weeks of consistent supplementation.
• Beyond joints, chondroitin sulphate is a critical structural component of the bladder’s protective GAG barrier, the corneal stroma and vitreous humour of the eye, and the extracellular matrix of skin and connective tissue — meaning supplementation supports multiple body systems simultaneously.
• Emerging research shows chondroitin sulphate acts as a prebiotic-like substrate for gut bacteria, increasing butyrate production and supporting microbial diversity — connecting supplementation directly to the gut–joint axis.
• Bonza uses GreenDroitin®, a plant-derived chondroitin sulphate extracted from Tremella fuciformis fungus, which demonstrates superior intestinal absorption without compromising the gut barrier — requiring approximately one-third of the dose of conventional animal-sourced chondroitin for effective results, with improved digestive comfort.

---

In this guide:

• Summary
• Key Takeways
• What Is Chondroitin Sulphate?
• Bioactive Compounds and Mechanism of Action
• Evidence-Based Benefits for Dogs
• Beyond Joints: Multi-System Support
• Chondroitin and Gut Health: The Gut–Joint Axis
• GreenDroitin®: Plant-Based Chondroitin with Superior Absorption
• Why Bonza Uses GreenDroitin®
• Safety, Dosage and What to Expect
• How to Support Your Dog’s Joint Health with Chondroitin
• Frequently Asked Questions
• Related Reading
• References
• Editorial Information
• About the Author

---

What Is Chondroitin Sulphate?

Chondroitin sulphate (CS) is a sulphated glycosaminoglycan — a long, linear polysaccharide chain composed of repeating disaccharide units of glucuronic acid and N-acetylgalactosamine, modified by sulphate groups at specific positions along the chain.¹ ² It is one of the most abundant structural molecules in the body, occurring naturally in cartilage, bone, skin, the cornea of the eye, blood vessel walls and the lining of the bladder and urinary tract.³ ⁴

In healthy cartilage, chondroitin sulphate chains are attached to core proteins to form large proteoglycan aggregates — principally aggrecan — that provide the tissue with its characteristic resistance to compression. The sulphated GAG chains attract and hold water molecules through their strong negative charge, creating a hydrated gel that cushions joints during movement and absorbs mechanical shock.¹ ³ This water-retention capacity is what makes cartilage such an effective shock absorber, and it is precisely this function that degrades as chondroitin sulphate is lost during the progression of osteoarthritis.

Chondroitin sulphate belongs to the broader GAG family alongside hyaluronic acid, heparan sulphate and its close structural relative, dermatan sulphate. While all GAGs contribute to extracellular matrix structure, chondroitin sulphate is distinguished by its particularly high concentration in articular cartilage and its dual role as both a structural molecule and a bioactive signalling compound that regulates inflammation, cell growth and tissue repair.² ⁴

Traditionally, supplemental chondroitin sulphate has been extracted from animal cartilage sources — primarily bovine trachea, porcine cartilage and shark cartilage. However, newer biotechnology approaches have enabled plant-based and fungal-origin alternatives, such as GreenDroitin® extracted from Tremella fuciformis, which offer comparable or superior biological activity with ethical and sustainability advantages.⁵

---

Bioactive Compounds and Mechanism of Action

Chondroitin sulphate exerts its benefits through several distinct but interconnected mechanisms.

Enzyme inhibition and cartilage protection. One of the most clinically relevant actions of chondroitin sulphate is its ability to inhibit cartilage-degrading enzymes, including matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS enzymes). These enzymes are upregulated in osteoarthritis and progressively break down the cartilage extracellular matrix.¹ ² By suppressing their activity, chondroitin sulphate helps slow the erosion of cartilage that drives joint pain and stiffness. An in vitro study using canine and feline articular chondrocytes demonstrated that chondroitin sulphate treatment significantly reduced secretion of pro-inflammatory cytokines including TNF-α, IL-1, IL-8 and MMP-3, while simultaneously reducing oxidative stress and apoptosis.⁶

Stimulation of proteoglycan and collagen synthesis. Chondroitin sulphate provides the raw substrate for chondrocytes (cartilage-producing cells) to synthesise new proteoglycans and GAGs — the building blocks of healthy cartilage matrix. This anabolic effect complements its anti-catabolic enzyme-inhibiting actions, creating a dual mechanism that both protects existing cartilage and supports new cartilage formation.¹ ³

Anti-inflammatory signalling. Beyond its structural role, chondroitin sulphate modulates inflammatory pathways at the cellular level. Research demonstrates it can suppress NF-κB signalling — a master regulator of inflammation — and reduce the production of nitric oxide and prostaglandin E₂ in articular cartilage.² ⁶ This anti-inflammatory activity helps break the self-perpetuating cycle of inflammation and cartilage destruction that characterises progressive osteoarthritis.

Water retention and joint lubrication. The densely negative sulphate groups on chondroitin chains attract and bind water molecules, maintaining cartilage hydration and the viscoelastic properties of synovial fluid. This hydration is essential for cartilage to function as an effective shock absorber during weight-bearing activity.¹ ³

Antioxidant protection. Chondroitin sulphate has been shown to reduce levels of reactive oxygen species (ROS) and increase the activity of endogenous antioxidant enzymes, including superoxide dismutase, in chondrocyte models. This antioxidant capacity helps protect cartilage cells from oxidative damage — a significant driver of age-related joint deterioration.⁶

---

Evidence-Based Benefits for Dogs

Joint mobility and osteoarthritis management

Chondroitin sulphate is one of the most extensively studied nutraceuticals in veterinary orthopaedics, most commonly evaluated in combination with glucosamine hydrochloride.

In a landmark randomised, double-blind, positive-controlled trial, McCarthy et al. (2007) enrolled 35 dogs with confirmed hip or elbow osteoarthritis to compare oral glucosamine HCl and chondroitin sulphate (Glu/CS) against carprofen (an NSAID). Dogs receiving Glu/CS showed statistically significant improvements in pain scores, weight-bearing and overall condition severity by day 70 of treatment (P<0.001). While the onset of benefit was slower than with carprofen, the improvements were clinically meaningful and persisted after treatment withdrawal at the day-98 reassessment.⁷

Gupta et al. (2012) conducted a prospective, randomised, double-blinded study in approximately 31–37 client-owned dogs weighing over 18 kg with moderate osteoarthritis, comparing glucosamine HCl plus chondroitin sulphate against undenatured type II collagen (UC-II) and placebo. The glucosamine–chondroitin group demonstrated improvements in overall pain, pain on limb manipulation and clinical condition over the 150-day study period.⁸

A 2022 randomised, placebo-controlled, double-blinded trial by Daghio et al. tested a multi-ingredient supplement containing chondroitin sulphate, glucosamine, hyaluronic acid and Boswellia serrata in 40 dogs with osteoarthritis for 60 days. The treatment group showed significantly reduced chronic pain (measured by Helsinki Chronic Pain Index) and clinical signs compared to placebo, with no adverse effects reported.⁹

More recently, a 2024 in vitro study by Xia et al. using canine articular chondrocytes confirmed that high-purity chondroitin sulphate (800 μg/mL) significantly enhanced cell viability, reduced oxidative stress, suppressed pro-inflammatory cytokine secretion (including IL-1, TNF-α, IL-8, IL-10 and MMP-3) and reduced chondrocyte apoptosis. The researchers concluded that CS purity is a critical factor in therapeutic efficacy.⁶

An important note on evidence quality. The veterinary literature on chondroitin and glucosamine includes both positive and equivocal results. A 2017 systematic review noted that approximately half of preclinical evaluations showed chondroprotective effects, with inconsistencies attributed to variations in product purity, dosing regimens, study duration and assessment methods.¹⁰ The emerging scientific consensus, supported by the most recent in vitro evidence, points to purity and source quality as the critical determinants of efficacy — which underscores the importance of ingredient selection in supplement formulation.⁶

Synergy with glucosamine HCl

Chondroitin sulphate and glucosamine hydrochloride work through complementary mechanisms. While glucosamine stimulates the synthesis of glycosaminoglycans and proteoglycans (the cartilage building blocks), chondroitin sulphate inhibits the enzymes that break them down. This creates a synergistic relationship: glucosamine builds new cartilage matrix while chondroitin protects existing structures from degradation.¹ ³ ⁷ The combination is more commonly studied and recommended than either compound alone, and most veterinary joint protocols include both.

---

Beyond Joints: Multi-System Support

Chondroitin sulphate’s distribution throughout the body extends its therapeutic relevance well beyond articular cartilage. Its presence in the bladder, eye, skin and digestive tract means that oral supplementation may support multiple organ systems simultaneously.

Bladder and urinary tract health

The inner lining of the bladder (urothelium) is protected by a glycosaminoglycan (GAG) barrier layer, and chondroitin sulphate is the only sulphated GAG located on the urothelial luminal surface that has been shown to contribute directly to bladder barrier function.¹¹ When this GAG layer is compromised — as occurs in interstitial cystitis, recurrent urinary tract infections and chemical cystitis — the bladder wall becomes permeable to urinary irritants, triggering inflammation and pain.¹² ¹³

In human and comparative veterinary medicine, intravesical hyaluronic acid–chondroitin sulphate therapy is an established treatment for restoring the damaged GAG layer in these conditions.¹³ Importantly, a 2019 study in the American Journal of Veterinary Research demonstrated that oral chondroitin sulphate supplementation (20–30 mg/kg, twice daily) in healthy dogs modestly but measurably increased urinary chondroitin sulphate concentrations within 24 hours. The researchers noted a potential therapeutic benefit of persistently increased urinary CS for preventing recurrent urinary tract infections in dogs.¹⁴

In dogs, low concentrations of urinary GAGs have been associated with increased susceptibility to recurrent urinary infections and urolithiasis, suggesting that maintaining adequate GAG levels through supplementation may provide a protective benefit.¹⁵

Eye support

Chondroitin sulphate is a critical structural component of the corneal stroma and the vitreous humour of the eye, where it helps maintain tissue transparency, hydration and structural integrity.¹⁶ In veterinary ophthalmology, chondroitin sulphate has established therapeutic applications.

Ledbetter et al. (2006) evaluated antimicrobial–chondroitin sulphate ophthalmic solutions in 80 dogs with spontaneous chronic corneal epithelial defects (SCCED). After four weeks of treatment, 81% of affected eyes had healed — results that compared favourably with other published medical and surgical therapies.¹⁷ Chondroitin sulphate ophthalmic solutions have also demonstrated efficacy as tear substitutes in dogs with keratoconjunctivitis sicca (dry eye), where studies show they restore corneal surface integrity, reduce inflammation through NF-κB inhibition, and maintain tear stability on the corneal surface.¹⁸

While these studies used topical formulations rather than oral supplementation, they confirm chondroitin sulphate’s fundamental biological role in ocular tissue health. Oral supplementation contributes to the systemic pool of GAGs available for eye tissue maintenance.

Skin and connective tissue resilience

Chondroitin sulphate and its structural relative dermatan sulphate are abundantly distributed in the extracellular matrix of skin and connective tissue, where they play essential structural roles in maintaining tissue viscoelasticity through their immobilised sulphate groups.¹⁹ ²⁰ These GAG chains bind growth factors — including fibroblast growth factor (FGF) and keratinocyte growth factor — that regulate wound healing, tissue remodelling and collagen organisation.¹⁹ ²⁰ ²¹

CS–proteoglycans are particularly abundant in the dermis, where they contribute to skin hydration, elasticity and resilience. Their role in binding and potentiating growth factor activity means they are integral to the skin’s capacity for repair and renewal.²⁰ ²¹

Digestive support

Chondroitin sulphate is a component of the GAG layer that lines the gastrointestinal mucosa. Oral chondroitin has been shown to replenish this protective glycosaminoglycan layer, supporting the mucous membrane integrity of the intestinal tract.²² This protective function parallels its role in the bladder, where the GAG layer shields underlying tissue from damaging substances.

---

Chondroitin and Gut Health: The Gut–Joint Axis

One of the most significant recent developments in chondroitin sulphate research is the growing understanding of its interaction with the gut microbiome connection — a connection that links oral supplementation directly to systemic joint health through the gut–joint axis.

Chondroitin sulphate has relatively low oral bioavailability — estimated at approximately 5–15% in dogs — which means that a substantial proportion of ingested CS reaches the colon intact, where it becomes available as a substrate for gut bacteria.²³ ²⁴ Far from being a limitation, this characteristic positions chondroitin sulphate as a prebiotic-like compound with emerging evidence of meaningful microbiome-modulatory effects.

A pivotal 2017 study published in Scientific Reports demonstrated that chondroitin sulphate disaccharides significantly modified the structure and function of the murine gut microbiome. Key findings included a significant increase in fecal butyrate concentration (butyrate being a potent anti-inflammatory short-chain fatty acid), a reduction in inflammatory Proteobacteria, a significant decrease in blood lipopolysaccharide (LPS) levels under stress conditions, and an increase in Bacteroides acidifaciens populations associated with immunomodulatory effects.²⁵

A 2019 systematic review of animal and human studies found moderate-quality evidence for an association between CS supplementation and increased abundance of the genus Bacteroides in the gut, along with increases in SCFA-producing bacteria and Bacteroidales S24-7 family members known to process glycans and increase during treatment-induced remission in colitis models.²⁴

A 2019 randomised, double-blind, placebo-controlled crossover trial in humans further confirmed that glucosamine and chondroitin supplementation significantly altered gut microbial community structure, with individual variation in response suggesting that baseline microbiome composition may influence therapeutic outcomes.²⁶

The significance of this gut–microbiome connection for joint health is substantial. A growing body of research implicates the gut microbiome in the pathogenesis of osteoarthritis through several mechanisms: systemic inflammation driven by microbial metabolites including LPS; altered short-chain fatty acid production affecting immune regulation; and compromised intestinal barrier integrity allowing pro-inflammatory molecules to enter systemic circulation and reach joint tissues.²⁷ Chondroitin sulphate’s ability to increase butyrate production, reduce circulating LPS and support beneficial microbial populations means that its gut-level activity may contribute meaningfully to its systemic joint-protective effects — independent of any direct cartilage-level action.

This dual mechanism — local prebiotic support in the gut plus systemic anti-inflammatory and chondroprotective effects from absorbed CS — places chondroitin sulphate at the intersection of gut health and joint health, directly supporting Bonza’s “One Gut. Whole Dog.” philosophy and the gut–joint axis framework.

---

GreenDroitin®: Plant-Based Chondroitin with Superior Absorption

Bonza’s Bounce and Boost formulations use GreenDroitin®, a next-generation plant-derived chondroitin sulphate extracted from the Tremella fuciformis fungus (commonly known as snow fungus or silver ear mushroom). This represents a fundamental departure from conventional animal-sourced chondroitin — and the science supports this choice on multiple levels.

Source and extraction

Tremella fuciformis is a well-characterised edible fungus naturally rich in polysaccharides that include glycosaminoglycan-like structures. Its polysaccharides have demonstrated multiple physiological properties including anti-inflammatory, antioxidant, immunomodulatory and neuroprotective effects.²⁸ GreenDroitin® is manufactured by Vivatis Pharma GmbH and is produced through a controlled extraction process that yields a low-molecular-weight chondroitin sulphate with a heterogeneous chemical-biological profile.⁵

Superior intestinal absorption

A key study published in the Journal of Functional Foods (2022) investigated GreenDroitin®’s biological properties using a 3D intestinal organoid system approved by both the FDA and EFSA to replicate the human intestinal environment. Researchers compared GreenDroitin®’s absorption rate against four commercially available chondroitin sulphate sources — fermentation-derived CS, chicken CS, bovine CS and shark CS — measuring intestinal barrier crossing at 2, 4 and 6 hours.⁵

The results were striking. GreenDroitin® achieved the highest absorption rate at every timepoint tested. At 2 hours, GreenDroitin® had already reached approximately 54% absorption — outperforming all competitors, the nearest of which (shark CS) reached approximately 49%. By 4 hours, GreenDroitin® peaked at approximately 75% absorption, compared with approximately 67% for shark CS, 62% for bovine CS, 57% for fermentation CS and 48% for chicken CS. At 6 hours, GreenDroitin® maintained approximately 70% absorption while all animal-derived and fermentation sources remained substantially lower.⁵

Crucially, this superior absorption was achieved without compromising intestinal barrier integrity — the organoid model confirmed that GreenDroitin® crossed the intestinal epithelium safely. Once absorbed, the plant-derived chondroitin exerted beneficial effects on chondrocytes, including modulation of ADAMTS-5 (aggrecanase-2), a key enzyme responsible for cartilage degradation in osteoarthritis.⁵

This superior bioavailability is clinically meaningful because one of the persistent challenges with conventional chondroitin supplementation is its low absorption rate. The manufacturer reports that GreenDroitin®’s enhanced absorption profile enables effective results at approximately one-third of the dose required by conventional animal-derived chondroitin sources — a significant formulation advantage that allows meaningful biological activity in smaller, more practical serving sizes.³² Unlike traditional animal-based chondroitin, GreenDroitin® has also been shown to pass through the digestive system effectively without causing digestive discomfort — an important consideration for daily supplementation compliance.³²

Anti-inflammatory effects of Tremella fuciformis polysaccharides

Additional research has confirmed the anti-inflammatory potential of Tremella fuciformis polysaccharides specifically in the context of osteoarthritis. A 2024 study using the human chondrocyte cell line T/C-28a2 demonstrated that Tremella fuciformis polysaccharide treatment reduced IL-6 secretion, upregulated osteoprotegerin (OPG) expression, downregulated pro-apoptotic Bax protein and NF-κB signalling, and inhibited intracellular reactive oxygen species levels in an LPS-induced inflammation model. The researchers concluded that Tremella fuciformis polysaccharide exhibited protective effects on cartilage tissue and resistance to cell apoptosis.²⁹

Comparative advantages over animal-derived sources

The choice of GreenDroitin® over conventional animal-derived chondroitin offers several distinct advantages. Animal-derived chondroitin (bovine, porcine, shark) varies considerably in purity, molecular weight and sulphation pattern depending on source species and extraction methods — variability that directly impacts therapeutic efficacy.⁶ Traditional animal-sourced chondroitin can also cause digestive discomfort in some animals, whereas GreenDroitin® passes through the digestive system without this issue.³² Shark-derived chondroitin raises serious sustainability and ethical concerns, contributing to the depletion of vulnerable marine ecosystems. By contrast, GreenDroitin® provides consistent quality from a controlled, sustainable fungal source with demonstrated superior absorption characteristics — requiring approximately one-third of the conventional dose for effective results — aligning with Bonza’s commitment to ethical, plant-based formulation without compromising scientific rigour.³²

---

Why Bonza Uses GreenDroitin®

Bonza’s Bounce contains 80 mg of chondroitin sulphate from GreenDroitin® per chewy, while Boost contains 45 mg per chewy. In both formulations, GreenDroitin® works as part of a comprehensive, multi-pathway approach to joint health.

Synergy with Bounce’s formulation partners. In Bounce, GreenDroitin® works alongside glucosamine HCl (240 mg), MSM (120 mg), hyaluronic acid (5 mg), avocado-soybean unsaponifiables (10 mg), Boswellia serrata (10 mg) and Curcuma longa (10 mg) to create a joint-support matrix that addresses cartilage structure, inflammation, synovial fluid quality and antioxidant protection simultaneously. The established synergy between chondroitin and glucosamine — where glucosamine stimulates cartilage synthesis while chondroitin inhibits its degradation — is amplified by ASU’s proven chondroprotective effects, boswellia’s 5-lipoxygenase inhibition and curcumin’s NF-κB modulation.⁷ ⁸ ⁹

Synergy with Boost’s formulation partners. In Boost, GreenDroitin® (45 mg) combines with glucosamine HCl (182 mg), N-acetyl-D-glucosamine (72.93 mg), MSM (90 mg), hyaluronic acid (7.5 mg), Boswellia serrata (15 mg), Curcuma longa (10.5 mg) and Zingiber officinalis (15 mg). The inclusion of Calsporin® (Bacillus velezensis, 75 mg) and Lactobacillus helveticus (5 mg) in Boost provides direct probiotic support that complements chondroitin’s prebiotic-like microbiome effects through the gut–joint axis.

The GreenDroitin® advantage. Given the in vitro evidence that CS purity is a critical factor in therapeutic efficacy,⁶ Bonza’s choice of GreenDroitin® — with its demonstrated superior intestinal absorption, consistent quality profile and digestive comfort — represents a deliberate investment in ingredient quality. With effective results reported at approximately one-third of the dose required by conventional chondroitin sources,³² GreenDroitin® delivers meaningful biological activity at the supplemental doses included in each chewy. Its plant-based origin means no contribution to overfishing, shark cartilage harvesting or intensive livestock farming, while its low-molecular-weight profile and superior absorption characteristics align with Bonza’s commitment to ethical, plant-based formulation without compromising scientific rigour.⁵

---

Safety, Dosage and What to Expect

Chondroitin sulphate has an excellent safety profile. It is a naturally occurring compound in the body, and supplemental chondroitin is well-tolerated in the vast majority of dogs. Potential adverse effects are limited to occasional mild gastrointestinal effects such as flatulence and stool softening.³⁰

Typical veterinary dosing. General veterinary recommendations for chondroitin sulphate range from 15 to 30 mg per kg of body weight daily, often with a loading phase at the higher end of this range for the first 4–6 weeks before reducing to a maintenance dose.³⁰ ³¹ The chondroitin component is often dosed in combination with glucosamine, and the two are typically co-administered for synergistic effect.

Onset of effect. Unlike NSAIDs, which provide rapid symptomatic relief, chondroitin sulphate works gradually through structural and metabolic mechanisms. Most veterinary references suggest that 6–10 weeks of consistent daily supplementation may be necessary before clinical improvements become apparent.⁷ ³⁰ This slower onset reflects chondroitin’s mechanism: it takes time to inhibit degradative enzymes, build new cartilage matrix and modulate inflammatory pathways at a tissue level.

Long-term use. Chondroitin sulphate is appropriate for long-term, ongoing supplementation. Its benefits are maintained with continuous use and typically decline after cessation, as demonstrated in the McCarthy et al. trial where improvements persisted at the day-98 post-treatment assessment but the trajectory suggested gradual return toward baseline.⁷

Precautions. Dogs with liver or kidney disease should use chondroitin under veterinary supervision. Chondroitin may interact with anticoagulant medications (warfarin, heparin) due to its structural similarity to heparin. As always, consult your veterinarian before adding any supplement to your dog’s regime.³⁰

---

How to Support Your Dog’s Joint Health with Chondroitin

---

Frequently Asked Questions

---

Related Reading

• Glucosamine HCl for Dogs: Joint Mobility & Inflammation Support
• Avocado-Soybean Unsaponifiables (ASU) for Dogs: Joint Protection & Mobility Support
• Best Joint Supplements for Dogs: Science-Informed Bioactive Ingredients
• The Gut–Joint Axis: How Your Dog’s Gut Microbiome Shapes Joint Health
• The Gut Microbiome: Your Dog’s Hidden Health Command Centre
• Best Probiotics for Dogs: A Complete Guide
• Best Prebiotics for Dogs: A Complete Guide

---

References

1. Beale BS. Use of nutraceuticals and chondroprotectants in osteoarthritic dogs and cats. Veterinary Clinics of North America: Small Animal Practice. 2004;34(1):271–289. doi:10.1016/j.cvsm.2003.09.008
2. Monfort J, Pelletier JP, Garcia-Giralt N, Martel-Pelletier J. Biochemical basis of the effect of chondroitin sulphate on osteoarthritis articular tissues. Annals of the Rheumatic Diseases. 2008;67(6):735–740. doi:10.1136/ard.2006.068882
3. Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: A review. Open Veterinary Journal. 2017;7(1):36–49. doi:10.4314/ovj.v7i1.6
4. Malavaki C, Mizumoto S, Karamanos N, Sugahara K. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connective Tissue Research. 2008;49(3):133–139. doi:10.1080/03008200802148546
5. Galla R, Ruga S, Ferrari S, Saccone S, Saccuman L, Invernizzi M, Uberti F. In vitro analysis of the effects of plant-derived chondroitin sulfate from intestinal barrier to chondrocytes. Journal of Functional Foods. 2022;98:105285. doi:10.1016/j.jff.2022.105285 [GreenDroitin® study — Vivatis Pharma / Tremella fuciformis]
6. Bai H, Liu T, Wang H, Li Y, Wang Z. Chondroitin sulfate alleviated lipopolysaccharide-induced arthritis in feline and canine articular chondrocytes through regulation of neurotrophic signaling pathways and apoptosis. Tissue and Cell. 2024;92:102660. doi:10.1016/j.tice.2024.102660
7. McCarthy G, O’Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Veterinary Journal. 2007;174(1):54–61. doi:10.1016/j.tvjl.2006.02.015
8. Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. Journal of Animal Physiology and Animal Nutrition. 2012;96(5):770–777. doi:10.1111/j.1439-0396.2011.01166.x
9. Martello E, Bigliati M, Adami R, Biasibetti E, Bisanzio D, Meineri G, Bruni N. Efficacy of a dietary supplement in dogs with osteoarthritis: A randomized placebo-controlled, double-blind clinical trial. PLoS One. 2022 Feb 16;17(2):e0263971. doi: 10.1371/journal.pone.0263971. PMID: 35171954; PMCID: PMC8849458.
10. Fernández-Martín S, González-Cantalapiedra A, Muñoz F, García-González M, Permuy M, López-Peña M. Glucosamine and chondroitin sulfate: Is there any scientific evidence for their effectiveness as disease-modifying drugs in knee osteoarthritis preclinical studies? — A systematic review from 2000 to 2021. Animals. 2021;11(6):1608. doi:10.3390/ani11061608
11. Janssen DAW, van Wijk XMR, Jansen KCFJ, et al. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. Journal of Urology. 2013;189(1):336–342. doi:10.1016/j.juro.2012.09.022
12. Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology. 2007;69(4 Suppl):9–16. doi:10.1016/j.urology.2006.03.084
13. Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Therapeutic Advances in Urology. 2011;3(5):223–232. doi:10.1177/1756287211418723
14. Wood MW, Lepold AM, Tesfamichael D, Barrett-Wilt GA. Effect of twice-daily oral administration of a chondroitin sulfate-containing supplement on urine chondroitin sulfate concentrations in dogs. American Journal of Veterinary Research. 2019;80(8):799–804. doi:10.2460/ajvr.80.8.799
15. Osório NB et al. Urinary glycosaminoglycans determination, by colorimetric method using DMB in alkaline solution, in healthy dogs. WSAVA 2002 Congress Proceedings. [Conference abstract — no DOI available]
16. Inatani M, Tanihara H, Honjo M, Hangai M, Kresse H, Honda Y. Chondroitin sulfate proteoglycans are structural renewable constituents of the rabbit vitreous body. Current Eye Research. 2005;30(5):395–404. doi:10.1080/02713680590934148
17. Ledbetter EC, Munger RJ, Ring RD, Scarlett JM. Efficacy of two chondroitin sulfate ophthalmic solutions in the therapy of spontaneous chronic corneal epithelial defects and ulcerative keratitis associated with bullous keratopathy in dogs. Veterinary Ophthalmology. 2006;9(2):77–87. doi:10.1111/j.1463-5224.2006.00439.x
18. Williams D, Middleton S, Fattahian H, Moridpour R. Comparison of hyaluronic acid-containing topical eye drops with carbomer-based topical ocular gel as a tear replacement in canine keratoconjunctivitis sicca: A prospective study in twenty five dogs. Vet Res Forum. 2012;3(4):229-232.
19. Zhang B, Chi L. Chondroitin Sulfate/Dermatan Sulfate-Protein Interactions and Their Biological Functions in Human Diseases: Implications and Analytical Tools. Front Cell Dev Biol. 2021 Aug 6;9:693563. doi: 10.3389/fcell.2021.693563. PMID: 34422817; PMCID: PMC8377502.
20. Mizumoto S and Yamada S (2021) An Overview of in vivo Functions of Chondroitin Sulfate and Dermatan Sulfate Revealed by Their Deficient Mice. Front. Cell Dev. Biol. 9:764781. doi: 10.3389/fcell.2021.764781
21. Trowbridge JM, Rudisill JA, Ron D, Gallo RL. Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7). Journal of Biological Chemistry. 2002;277(45):42815–42820. doi:10.1074/jbc.M204959200
22. Oral chondroitin replenishes the glycosaminoglycan layer of the bladder and intestinal tract mucous membranes. [Multiple sources — see Damiano & Cicione 2011; no single DOI]
23. Adebowale, Abimbola & Cox, Donna & Liang, Zhongming & Eddington, Natalie. (2000). Analysis of glucosamine and chondroitin sulfate content in marketed products and the Caco-2 permeability of chondroitin sulfate raw materials. Journal of the American Nutraceutical Association. 3.
24. Shmagel A, Demmer R, Knights D, et al. The effects of glucosamine and chondroitin sulfate on gut microbial composition: A systematic review of evidence from animal and human studies. Nutrients. 2019;11(2):294. doi:10.3390/nu11020294
25. Liu F, Zhang N, Li Z, et al. Chondroitin sulfate disaccharides modified the structure and function of the murine gut microbiome under healthy and stressed conditions. Scientific Reports. 2017;7:6783. doi:10.1038/s41598-017-05860-6
26. Navarro, S.L.; Levy, L.; Curtis, K.R.; Lampe, J.W.; Hullar, M.A.J. Modulation of Gut Microbiota by Glucosamine and Chondroitin in a Randomized, Double-Blind Pilot Trial in Humans. Microorganisms 2019, 7, 610. https://doi.org/10.3390/microorganisms7120610
27. Wei Z, Li F and Pi G (2022) Association Between Gut Microbiota and Osteoarthritis: A Review of Evidence for Potential Mechanisms and Therapeutics. Front. Cell. Infect. Microbiol. 12:812596. doi: 10.3389/fcimb.2022.812596
28. Huang TY, Yang FL, Chiu HW, Chao HC, Yang YJ, Sheu JH, Hua KF, Wu SH. An Immunological Polysaccharide from Tremella fuciformis: Essential Role of Acetylation in Immunomodulation. Int J Mol Sci. 2022 Sep 8;23(18):10392. doi: 10.3390/ijms231810392. PMID: 36142298; PMCID: PMC9499394.
29. Tan Minying, Dai Chuanjing, Lu Xuemin, Wang Yigang, Guan Lei, Cheng Yong. Proliferation and anti-inflammatory effects of Tremella fuciformis polysaccharide on human chondrocytes. Science and Technology of Food Industry. 2024;45(1):1–8. doi:10.13386/j.issn1002-0306.2023060077
30. Plumb DC. Plumb’s Veterinary Drug Handbook. 9th ed. Stockholm, WI: PharmaVet Inc; 2018. [Textbook — no DOI. Chondroitin sulphate monograph: dosing, adverse effects, drug interactions]
31. Glucosamine and chondroitin dosage https://pmc.ncbi.nlm.nih.gov/articles/PMC5356289/
32. Vivatis Pharma GmbH. GreenDroitin® — The next-generation vegan chondroitin sulphate. Product technical documentation. Available at: https://www.greendroitin.com/ and https://en.vivatis.de/our-developments/ [Manufacturer data — 1/3 dose efficacy claim and digestive comfort profile]

---

Editorial Information

Editorial Information
Published	February 2026
Last updated	February 2026 — New article
Reviewed by	Glendon Lloyd, Dip. Canine Nutrition (Dist.), Dip. Canine Nutrigenomics (Dist.)
Next review	August 2026
Author	Glendon Lloyd
Disclaimer	This article is for educational purposes only and is not a substitute for professional veterinary advice. Always consult your veterinarian before adding supplements to your dog’s diet.

---

About the Author

Glendon Lloyd · Dip. Canine Nutrition (Dist.) · Dip. Canine Nutrigenomics (Dist.)

Founder and CEO of Bonza, Glendon holds Diplomas in Canine Nutrition and Canine Nutrigenomics, both with Distinction. His mission — Add years to their life, and life to their years — drives Bonza’s science-led approach to plant-based canine nutrition. Glendon reads 5–6 peer-reviewed studies weekly and oversees the formulation of every Bonza product, ensuring each ingredient is selected for its evidence-based contribution to whole-body canine health through the gut microbiome.

Read Glendon’s full bio →